Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10052411 | 0.87 | MAPT (0.33) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL8922089 | 0.77 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2LDHAMAPT | |
| SCHEMBL21607007 | 0.75 | SMN1; SMN2 (0.36) | NPC1RAB9ASMN1; SMN2MAPTHCAR2 | |
| SCHEMBL21606987 | 0.72 | NPC1 (0.45) | NPC1RAB9ASMN1; SMN2LDHAMAPT | |
| SCHEMBL890158 | 0.70 | KDM4E (0.49) | NPC1RAB9ASMN1; SMN2MAPTHSD17B10 | |
| SCHEMBL8473452 | 0.69 | LDHA (0.55) | NPC1RAB9ALDHAMAPTALDH1A1 | |
| SCHEMBL21606992 | 0.68 | OGA (0.38) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL13747654 | 0.68 | RAB9A (0.51) | NPC1RAB9ASMN1; SMN2LDHAMAPT | |
| SCHEMBL7921134 | 0.67 | SMN1; SMN2 (0.43) | NPC1RAB9ASMN1; SMN2MAPTHCAR2 | |
| SCHEMBL21606993 | 0.67 | MAPT (0.35) | NPC1RAB9ASMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178531-B2 | Antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20110218175-A1 | ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218175-A1 | ANTIVIRAL AGENTS | EIF2AK2, HAVCR2, MAVS | NPC1 826/4885RAB9A 2172/4885SMN1; SMN2 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.